https://simplecast.com Labcorp Perspectives: Oncology Explore the ever-evolving world of cancer care in our insightful content series, Labcorp Perspectives as we delve into the latest advancements in oncology diagnostics and their impact on patient outcomes. Each episode brings together leading oncology experts to discuss: • Groundbreaking research: Uncovering the cutting-edge science shaping the future of cancer treatment • Practical applications: Learning how precision medicine translates from lab to the clinic • Real-world challenges: Exploring the hurdles faced in oncology care and discovering potential solutions More than just information, this series fosters collaboration and unbiased education. Labcorp Perspectives not only empowers healthcare professionals and researchers but also patients to stay informed, inspired and at the forefront of medical oncology. 2025 Labcorp en Thu, 19 Feb 2026 05:00:00 +0000 Thu, 19 Feb 2026 05:00:12 +0000 https://labcorp-perspectives-oncology.simplecast.com Labcorp Perspectives: Oncology https://image.simplecastcdn.com/images/748ca0d2-56fa-423c-8807-519c7b1cbe07/9011046f-a40a-478b-97ad-a286da7925f3/3000x3000/artwork-205c.jpg?aid=rss_feed https://labcorp-perspectives-oncology.simplecast.com episodic Explore the ever-evolving world of cancer care in our insightful content series, Labcorp Perspectives as we delve into the latest advancements in oncology diagnostics and their impact on patient outcomes. Each episode brings together leading oncology experts to discuss: • Groundbreaking research: Uncovering the cutting-edge science shaping the future of cancer treatment • Practical applications: Learning how precision medicine translates from lab to the clinic • Real-world challenges: Exploring the hurdles faced in oncology care and discovering potential solutions More than just information, this series fosters collaboration and unbiased education. Labcorp Perspectives not only empowers healthcare professionals and researchers but also patients to stay informed, inspired and at the forefront of medical oncology. Labcorp false https://feeds.simplecast.com/Pa0jeTeI Labcorp stories@amazemedialabs.com 85626348-a2cf-49b2-a693-b48919639a8d Navigating the Future of CDXs in Oncology How are companion diagnostics (CDXs) transforming the landscape of precision oncology? In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs welcomes CDX expert Dawn McHugh, Director of Precision Oncology CDx at Labcorp, for a deep dive into the evolving world of companion diagnostics.

You’ll learn what defines a true CDX, how it differs from other biomarker tests, and why integrating it with targeted therapies is essential for matching the right patient to the right treatment. Dawn McHugh guides us through real-world examples—from HER2 and EGFR to the latest in liquid biopsy—explaining how these diagnostics are expanding access, shaping new therapies, and accelerating the pace of cancer innovation. The conversation explores development timelines, regulatory hurdles, the value of early collaboration, and emerging technologies like AI and decentralized NGS.

Whether you’re an oncologist, researcher, or pharma partner, this episode delivers actionable insights on the present and future impact of CDXs in oncology care.

Tune in for a dynamic, forward-looking discussion and gain a new perspective on the science fueling tomorrow’s breakthroughs.

Follow Us

Presented by Labcorp Oncology
www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 19 Feb 2026 05:00:00 +0000 stories@amazemedialabs.com (Dr. Rebecca Previs, Dawn McHugh) https://labcorp-perspectives-oncology.simplecast.com/episodes/navigating-the-future-of-cdxs-in-oncology-tZurZuZw How are companion diagnostics (CDXs) transforming the landscape of precision oncology? In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs welcomes CDX expert Dawn McHugh, Director of Precision Oncology CDx at Labcorp, for a deep dive into the evolving world of companion diagnostics.

You’ll learn what defines a true CDX, how it differs from other biomarker tests, and why integrating it with targeted therapies is essential for matching the right patient to the right treatment. Dawn McHugh guides us through real-world examples—from HER2 and EGFR to the latest in liquid biopsy—explaining how these diagnostics are expanding access, shaping new therapies, and accelerating the pace of cancer innovation. The conversation explores development timelines, regulatory hurdles, the value of early collaboration, and emerging technologies like AI and decentralized NGS.

Whether you’re an oncologist, researcher, or pharma partner, this episode delivers actionable insights on the present and future impact of CDXs in oncology care.

Tune in for a dynamic, forward-looking discussion and gain a new perspective on the science fueling tomorrow’s breakthroughs.

Follow Us

Presented by Labcorp Oncology
www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Navigating the Future of CDXs in Oncology Dr. Rebecca Previs, Dawn McHugh 00:26:21 CDX expert Dawn McHugh joins Dr. Rebecca Previs to unpack the role of companion diagnostics in precision oncology and the future of cancer care. CDX expert Dawn McHugh joins Dr. Rebecca Previs to unpack the role of companion diagnostics in precision oncology and the future of cancer care. false full 9 4d3accfc-239a-49e4-816d-872efa371f2f FFPE: The Workhorse Behind NGS Testing In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs is joined by Dr. Kyle Strickland, Director of Medical Affairs and pathologist at Labcorp, and Dr. Erin Newburn, field application scientist and genomicist, for a deep dive into tissue stewardship and the pivotal role of FFPE specimens in precision oncology.

Together, the team demystifies how formalin-fixed paraffin-embedded (FFPE) samples have become the gold standard in both clinical and research settings for biomarker testing. They discuss the science behind tissue preservation, compare FFPE to fresh and frozen samples, and reveal the unique challenges these specimens present for next-generation sequencing. Explore the crucial pre-analytical factors influencing sample quality and how emerging innovations are pushing the boundaries of what’s possible in cancer diagnostics, clinical trials, and translational research.

Whether you’re a clinician seeking to optimize patient care, a researcher navigating limited samples, or simply curious about the future of precision medicine, this conversation provides practical insights and actionable tips directly from the experts transforming the field.

Tune in now to discover how the workhorse of pathology is powering a new era in oncology.

Follow Us

Presented by Labcorp Oncology
www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Thu, 29 Jan 2026 05:00:00 +0000 stories@amazemedialabs.com (Dr. Kyle Strickland, Dr. Erin Newburn, Dr. Rebecca Previs) https://labcorp-perspectives-oncology.simplecast.com/episodes/ffpe-the-workhorse-behind-ngs-testing-oarngaek-E_sZKh8N In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs is joined by Dr. Kyle Strickland, Director of Medical Affairs and pathologist at Labcorp, and Dr. Erin Newburn, field application scientist and genomicist, for a deep dive into tissue stewardship and the pivotal role of FFPE specimens in precision oncology.

Together, the team demystifies how formalin-fixed paraffin-embedded (FFPE) samples have become the gold standard in both clinical and research settings for biomarker testing. They discuss the science behind tissue preservation, compare FFPE to fresh and frozen samples, and reveal the unique challenges these specimens present for next-generation sequencing. Explore the crucial pre-analytical factors influencing sample quality and how emerging innovations are pushing the boundaries of what’s possible in cancer diagnostics, clinical trials, and translational research.

Whether you’re a clinician seeking to optimize patient care, a researcher navigating limited samples, or simply curious about the future of precision medicine, this conversation provides practical insights and actionable tips directly from the experts transforming the field.

Tune in now to discover how the workhorse of pathology is powering a new era in oncology.

Follow Us

Presented by Labcorp Oncology
www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> FFPE: The Workhorse Behind NGS Testing Dr. Kyle Strickland, Dr. Erin Newburn, Dr. Rebecca Previs 00:33:38 Exploring FFPE’s impact on precision oncology, NGS innovation, and the future of tissue stewardship in cancer care with leading Labcorp experts. Exploring FFPE’s impact on precision oncology, NGS innovation, and the future of tissue stewardship in cancer care with leading Labcorp experts. false full 8 827ed337-2884-4bed-b00a-8792fbd73685 ctDNA Breakthroughs in Mesothelioma Care In this insightful episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs sits down with Dr. Mark Sausen, Labcorp's Head of Technology and Innovation, to break down a cutting-edge Phase II clinical trial exploring perioperative immunotherapy for resectable diffuse pleural mesothelioma, a rare and aggressive cancer.

Hear firsthand how the introduction of immune checkpoint blockade and an ultrasensitive tumor-informed ctDNA platform offers new hope for tracking and treating patients when imaging falls short. Dr. Sausen shares the technological breakthroughs behind molecular residual disease detection, the impact of ctDNA on progression-free survival, and practical challenges in implementing these assays across multicenter studies.

Whether you’re a clinician, researcher, or patient advocate, discover how molecular monitoring is changing the game for mesothelioma and rare cancers alike.

Tune in now to reimagine the future of oncology care.

Follow Us

Presented by Labcorp Oncology
www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Tue, 4 Nov 2025 05:00:00 +0000 stories@amazemedialabs.com (Dr. Mark Sausen, Dr. Rebecca Previs) https://labcorp-perspectives-oncology.simplecast.com/episodes/ctdna-breakthroughs-in-mesothelioma-care-g4FLRak5 In this insightful episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs sits down with Dr. Mark Sausen, Labcorp's Head of Technology and Innovation, to break down a cutting-edge Phase II clinical trial exploring perioperative immunotherapy for resectable diffuse pleural mesothelioma, a rare and aggressive cancer.

Hear firsthand how the introduction of immune checkpoint blockade and an ultrasensitive tumor-informed ctDNA platform offers new hope for tracking and treating patients when imaging falls short. Dr. Sausen shares the technological breakthroughs behind molecular residual disease detection, the impact of ctDNA on progression-free survival, and practical challenges in implementing these assays across multicenter studies.

Whether you’re a clinician, researcher, or patient advocate, discover how molecular monitoring is changing the game for mesothelioma and rare cancers alike.

Tune in now to reimagine the future of oncology care.

Follow Us

Presented by Labcorp Oncology
www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> ctDNA Breakthroughs in Mesothelioma Care Dr. Mark Sausen, Dr. Rebecca Previs 00:15:11 Exploring immunotherapy and ctDNA innovation in mesothelioma, where molecular monitoring may redefine early cancer detection and treatment. Exploring immunotherapy and ctDNA innovation in mesothelioma, where molecular monitoring may redefine early cancer detection and treatment. false full 7 2318e476-5fc6-461e-8cb1-512f537d9db5 Empowering Breast Cancer Patients: Biomarker Breakthroughs & Self-Advocacy In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs connects with Suzanne Garner, Senior Director of Strategic Partnerships at Outcomes4Me, to spotlight her remarkable journey as a breast cancer patient, advocate, and now leader in digital health. Suzanne shares her personal story, from an unexpected diagnosis and navigating overwhelming choices, to the pivotal discovery that empowered her to actively participate in her treatment decisions.

Together, they discuss the critical role of biomarker and genetic testing in shaping individualized treatment plans and the impact of patient-friendly technology, like the Outcomes4Me app, in driving health equity and expanding access to clinical trials. Learn how education, self-advocacy, and digital tools are changing the cancer care landscape, and why the partnership between patient and oncologist matters more than ever.

Tune in for hope, practical insights, and real-world tools for patients, providers, and caregivers alike.

Follow Us

Presented by Labcorp Oncology

www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Mon, 20 Oct 2025 04:00:00 +0000 stories@amazemedialabs.com (Suzanne Garner, Dr. Rebecca Previs) https://labcorp-perspectives-oncology.simplecast.com/episodes/empowering-breast-cancer-patients-biomarker-breakthroughs-self-advocacy-xXQNJDkA In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs connects with Suzanne Garner, Senior Director of Strategic Partnerships at Outcomes4Me, to spotlight her remarkable journey as a breast cancer patient, advocate, and now leader in digital health. Suzanne shares her personal story, from an unexpected diagnosis and navigating overwhelming choices, to the pivotal discovery that empowered her to actively participate in her treatment decisions.

Together, they discuss the critical role of biomarker and genetic testing in shaping individualized treatment plans and the impact of patient-friendly technology, like the Outcomes4Me app, in driving health equity and expanding access to clinical trials. Learn how education, self-advocacy, and digital tools are changing the cancer care landscape, and why the partnership between patient and oncologist matters more than ever.

Tune in for hope, practical insights, and real-world tools for patients, providers, and caregivers alike.

Follow Us

Presented by Labcorp Oncology

www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Empowering Breast Cancer Patients: Biomarker Breakthroughs & Self-Advocacy Suzanne Garner, Dr. Rebecca Previs 00:26:45 Suzanne Garner’s journey shows how education, advocacy, and technology are reshaping breast cancer patient care and clinical trial access. Suzanne Garner’s journey shows how education, advocacy, and technology are reshaping breast cancer patient care and clinical trial access. false full 6 b280c51a-dbbd-4ee0-998f-002f2555a806 Redefining Ovarian Cancer Care with Biomarkers In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs sits down with colleague and pathologist Dr. Kyle Strickland to explore the complexities of ovarian cancer and the evolving science shaping its diagnosis and treatment.

Together, they discuss how ovarian cancer is often misunderstood as a single disease, the importance of accurately classifying its subtypes, and the critical role biomarkers like HRD and RB1 play in improving outcomes. Dr. Strickland shares his latest research on RB1, explains how HRD testing is reshaping patient care, and highlights Labcorp’s advancements with OmniSeq Insight, designed to provide clinicians with deeper insights into tumor biology. Listeners will gain a clearer understanding of how these scientific developments are transforming precision oncology and opening the door to new possibilities for ovarian cancer patients.

Tune in to the full conversation now.

Follow Us

Presented by Labcorp Oncology
www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Mon, 8 Sep 2025 04:00:00 +0000 stories@amazemedialabs.com (Dr. Kyle Strickland, Dr. Rebecca Previs) https://labcorp-perspectives-oncology.simplecast.com/episodes/redefining-ovarian-cancer-care-with-biomarkers-Tijc2XZJ In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs sits down with colleague and pathologist Dr. Kyle Strickland to explore the complexities of ovarian cancer and the evolving science shaping its diagnosis and treatment.

Together, they discuss how ovarian cancer is often misunderstood as a single disease, the importance of accurately classifying its subtypes, and the critical role biomarkers like HRD and RB1 play in improving outcomes. Dr. Strickland shares his latest research on RB1, explains how HRD testing is reshaping patient care, and highlights Labcorp’s advancements with OmniSeq Insight, designed to provide clinicians with deeper insights into tumor biology. Listeners will gain a clearer understanding of how these scientific developments are transforming precision oncology and opening the door to new possibilities for ovarian cancer patients.

Tune in to the full conversation now.

Follow Us

Presented by Labcorp Oncology
www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Redefining Ovarian Cancer Care with Biomarkers Dr. Kyle Strickland, Dr. Rebecca Previs 00:14:11 Exploring ovarian cancer, biomarkers HRD & RB1, and how Labcorp innovations are advancing precision oncology. Exploring ovarian cancer, biomarkers HRD & RB1, and how Labcorp innovations are advancing precision oncology. false full 5 ec274db0-610d-49eb-a229-2a04c1e93907 Why Comprehensive Testing Matters—Ken Schlosser’s Lung Cancer Story A Real Story of Hope, Testing, and Targeted Care.

In this episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs speaks with Ken Schlosser about how biomarker testing informed his care plan after a stage IV lung cancer diagnosis in 2019.

Ken shares how a routine trip to the ER led to the discovery of an ALK+ alteration, and how comprehensive genomic profiling through OmniSeq helped guide a treatment path that has kept him thriving for more than six years.

They also discuss the role of patient education and advocacy in expanding access to precision testing, as well as why understanding your biomarker status can make a significant difference in care outcomes.

This episode offers an inspiring look at how data-driven decisions can transform lives and why testing is crucial from the outset.

Listen to the full conversation now.

Follow Us

Presented by Labcorp Oncology
www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Fri, 1 Aug 2025 04:00:00 +0000 stories@amazemedialabs.com (Ken Schlosser, Dr. Rebecca Previs) https://labcorp-perspectives-oncology.simplecast.com/episodes/why-comprehensive-testing-mattersken-schlossers-lung-cancer-story-eAzC0bCh A Real Story of Hope, Testing, and Targeted Care.

In this episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs speaks with Ken Schlosser about how biomarker testing informed his care plan after a stage IV lung cancer diagnosis in 2019.

Ken shares how a routine trip to the ER led to the discovery of an ALK+ alteration, and how comprehensive genomic profiling through OmniSeq helped guide a treatment path that has kept him thriving for more than six years.

They also discuss the role of patient education and advocacy in expanding access to precision testing, as well as why understanding your biomarker status can make a significant difference in care outcomes.

This episode offers an inspiring look at how data-driven decisions can transform lives and why testing is crucial from the outset.

Listen to the full conversation now.

Follow Us

Presented by Labcorp Oncology
www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Why Comprehensive Testing Matters—Ken Schlosser’s Lung Cancer Story Ken Schlosser, Dr. Rebecca Previs 00:23:16 Biomarker testing helped Ken Schlosser live with stage IV lung cancer for over 6 years. Here's how it shaped his care plan from the start. Biomarker testing helped Ken Schlosser live with stage IV lung cancer for over 6 years. Here's how it shaped his care plan from the start. false full 4 d1113594-aa8b-4e5f-bf8a-010d449c4e73 Rethinking How We Track and Treat Cancer Precision oncology is evolving fast, and staying ahead means rethinking how we test, monitor, and treat cancer.

In this episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs sits down with Dr. Michelle Green, senior manager of oncology genomics, to talk about the major highlights from the ASCO Annual Meeting.

They explore Labcorp’s HER2 expression study in breast cancer, which found significant changes in HER2 status over time, and what that means for retesting and clinical decisions. Michelle and Rebecca also discuss new data on HER3-targeting antibody-drug conjugates, including the potential for treating both breast and lung cancers, and advances in ctDNA testing across tumor types.

From molecular profiling to liquid biopsy, this episode provides a wide-ranging look at how new tools and emerging biomarkers are shaping the future of personalized oncology care.

Listen to the full conversation now.

Follow Us

Presented by Labcorp Oncology

www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Mon, 14 Jul 2025 04:00:00 +0000 stories@amazemedialabs.com (Dr. Rebecca Previs, Dr. Michelle Green) https://labcorp-perspectives-oncology.simplecast.com/episodes/rethinking-how-we-track-and-treat-cancer-IDb_sj9y Precision oncology is evolving fast, and staying ahead means rethinking how we test, monitor, and treat cancer.

In this episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs sits down with Dr. Michelle Green, senior manager of oncology genomics, to talk about the major highlights from the ASCO Annual Meeting.

They explore Labcorp’s HER2 expression study in breast cancer, which found significant changes in HER2 status over time, and what that means for retesting and clinical decisions. Michelle and Rebecca also discuss new data on HER3-targeting antibody-drug conjugates, including the potential for treating both breast and lung cancers, and advances in ctDNA testing across tumor types.

From molecular profiling to liquid biopsy, this episode provides a wide-ranging look at how new tools and emerging biomarkers are shaping the future of personalized oncology care.

Listen to the full conversation now.

Follow Us

Presented by Labcorp Oncology

www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Rethinking How We Track and Treat Cancer Dr. Rebecca Previs, Dr. Michelle Green 00:19:28 HER2, HER3, and MRD: Drs. Previs and Green break down ASCO highlights and what they mean for the future of cancer diagnostics. HER2, HER3, and MRD: Drs. Previs and Green break down ASCO highlights and what they mean for the future of cancer diagnostics. false full 3 e1bb0fe6-6e11-4eb4-93d4-7afc61364530 Tumor-Agnostic Therapies and the Future of HER2 in Oncology Tumor biology is rewriting the rules of cancer treatment.
In this episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs talks with Dr. Heidi Ko, Director of Medical Affairs at Labcorp and a breast medical oncologist, about the rapid evolution of tumor-agnostic therapies and HER2-targeted treatment strategies.

They unpack what these FDA approvals actually mean in clinical practice, why HER2 is becoming relevant far beyond breast and gastric cancer, and how biomarkers like ERBB2 amplification and HER2 protein expression are shaping decisions across tumor types.

Dr. Ko shares her insights from the DESTINY-PanTumor02 trial, discusses why tissue stewardship is more important than ever, and breaks down what oncologists need to know about interpreting HER2 data across IHC, FISH, and NGS.

Whether you’re navigating biomarker testing workflows or just trying to keep up with precision oncology’s fast pace, this episode offers timely context and clear clinical takeaways.

Tune in now.

Follow Us

Presented by Labcorp Oncology

www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Mon, 9 Jun 2025 04:00:00 +0000 stories@amazemedialabs.com (Dr. Rebecca Previs, Dr. Heidi Ko) https://labcorp-perspectives-oncology.simplecast.com/episodes/tumor-agnostic-therapies-and-the-future-of-her2-in-oncology-9RYz6rc7 Tumor biology is rewriting the rules of cancer treatment.
In this episode of Labcorp Perspectives: Oncology, host Dr. Rebecca Previs talks with Dr. Heidi Ko, Director of Medical Affairs at Labcorp and a breast medical oncologist, about the rapid evolution of tumor-agnostic therapies and HER2-targeted treatment strategies.

They unpack what these FDA approvals actually mean in clinical practice, why HER2 is becoming relevant far beyond breast and gastric cancer, and how biomarkers like ERBB2 amplification and HER2 protein expression are shaping decisions across tumor types.

Dr. Ko shares her insights from the DESTINY-PanTumor02 trial, discusses why tissue stewardship is more important than ever, and breaks down what oncologists need to know about interpreting HER2 data across IHC, FISH, and NGS.

Whether you’re navigating biomarker testing workflows or just trying to keep up with precision oncology’s fast pace, this episode offers timely context and clear clinical takeaways.

Tune in now.

Follow Us

Presented by Labcorp Oncology

www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Tumor-Agnostic Therapies and the Future of HER2 in Oncology Dr. Rebecca Previs, Dr. Heidi Ko 00:20:35 What tumor-agnostic approvals mean for HER2, NGS, and precision oncology — and how they’re changing treatment across cancer types. What tumor-agnostic approvals mean for HER2, NGS, and precision oncology — and how they’re changing treatment across cancer types. false full 2 ed834146-6460-4ec5-853b-65ebada708ad Why Genetic Testing Should Be Standard in Prostate Cancer Genetic testing is no longer optional — it’s essential.

Welcome to the first episode of Labcorp Perspectives: Oncology, where host Dr. Rebecca Previs sits down with Sarah Young, a genetic counselor and Clinical Program Manager for Oncology at Labcorp, to talk about the growing importance of genetic testing in prostate cancer care.

Sarah shares insights from the recent American Urological Association (AUA) conference, where she helped lead the first plenary session focused on genetic testing in urologic oncology. Together, they discuss the latest research supporting universal germline testing, the clinical relevance of both germline and somatic testing, and how this information can directly influence treatment decisions, including eligibility for targeted therapies like PARP inhibitors.

They also explore barriers to adoption, including provider education gaps, complex guidelines, and limited access to genetics professionals, and offer practical solutions like mainstream testing, digital education tools, and Labcorp’s post-test counseling support.

Hear how broader testing strategies are reshaping care pathways, improving outcomes, and helping to close gaps for high-risk and historically underserved patient populations.

Tune in now.

Follow Us

Presented by Labcorp Oncology
www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Mon, 19 May 2025 04:00:00 +0000 stories@amazemedialabs.com (Dr. Rebecca Previs, Sarah Young) https://labcorp-perspectives-oncology.simplecast.com/episodes/why-genetic-testing-should-be-standard-in-prostate-cancer-2bH0VuFq Genetic testing is no longer optional — it’s essential.

Welcome to the first episode of Labcorp Perspectives: Oncology, where host Dr. Rebecca Previs sits down with Sarah Young, a genetic counselor and Clinical Program Manager for Oncology at Labcorp, to talk about the growing importance of genetic testing in prostate cancer care.

Sarah shares insights from the recent American Urological Association (AUA) conference, where she helped lead the first plenary session focused on genetic testing in urologic oncology. Together, they discuss the latest research supporting universal germline testing, the clinical relevance of both germline and somatic testing, and how this information can directly influence treatment decisions, including eligibility for targeted therapies like PARP inhibitors.

They also explore barriers to adoption, including provider education gaps, complex guidelines, and limited access to genetics professionals, and offer practical solutions like mainstream testing, digital education tools, and Labcorp’s post-test counseling support.

Hear how broader testing strategies are reshaping care pathways, improving outcomes, and helping to close gaps for high-risk and historically underserved patient populations.

Tune in now.

Follow Us

Presented by Labcorp Oncology
www.oncology.labcorp.com


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

]]> Why Genetic Testing Should Be Standard in Prostate Cancer Dr. Rebecca Previs, Sarah Young 00:19:00 Hear why universal genetic testing matters in prostate cancer — plus, how it can improve treatment, equity, and outcomes for patients everywhere. Hear why universal genetic testing matters in prostate cancer — plus, how it can improve treatment, equity, and outcomes for patients everywhere. false full 1